Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide derivatives. Identification of a bifunctional hydrogen bond area related to the inverse agonism

Journal of Medicinal Chemistry

Volumn 52, Issue 15, 2009, Pages 4668-4682

  Guerrini, Gabriella ^a   Ciciani, Giovanna ^a   Cambi, Giovanni ^a   Bruni, Fabrizio ^a   Selleri, Silvia ^a   Guarino, Chiara ^a   Melani, Fabrizio ^b   Montali, Marina ^c   Martini, Claudia ^c   Ghelardini, Carla ^d   Norcini, Monica ^d   Costanzo, Annarella ^a  

^a Laboratorio di Progettazione   (Italy)

^b Dipartimento di Scienze Farmaceutiche   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 IODO 8 (1 PHENYLETHOXY)PYRAZOLO[5,1 C][1,2,4]BENZOTRIAZINE 5 OXIDE; 3 IODO 8 (PYRIDIN 4 YLMETHOXY)PYRAZOLO[5,1 C][1,2,4]BENZOTRIAZINE 5 OXIDE; 3 IODO 8 BENZYLOXYPYRAZOLO[5,1 C][1,2,4]BENZOTRIAZINE 5 OXIDE; 3 IODO 8 PHENOXYPYRAZOLO[5,1 C][1,2,4]BENZOTRIAZINE 5 OXIDE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ALCOHOL; DIAZEPAM; FLUMAZENIL; FUNCTIONAL GROUP; PYRAZOLO[5,1 C][1,2,4]BENZOTRIAZINE 5 OXIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ANXIETY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; HYDROPHILICITY; IN VIVO STUDY; INVERSE AGONISM; LEARNING; LIPOPHILICITY; MEMORY; MOLECULAR MODEL; MOTOR COORDINATION; MOUSE; NONHUMAN; PHARMACOPHORE; STATISTICAL ANALYSIS; STEREOCHEMISTRY; SUBSTITUTION REACTION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; CATTLE; DRUG INVERSE AGONISM; HYDROGEN BONDING; MALE; MICE; MODELS, MOLECULAR; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECEPTORS, GABA-A; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

EID: 68549132505     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801599a     Document Type: Article

References (37)

1. A receptors: Subtypes, Regional Distribution, and Function. J. Clin. Sleep Med. 2006, 2, S7-11.
2. A receptor diversity and pharmacology. Cell Tissue Res. 2006, 326, 505-516.
3. A receptors as target for different classes of drugs. Drugs Future 2006, 31, 685-694.
4. Sieghart, W. Structure, Pharmacology and Function of GABAA Receptor subtypes. Adv. Pharmacol. 2006, 54, 231-263.
5. Cooke, A. J.; Hamilton, N. M. alpha-Subunit selective modulators of GABAA receptor function as CNS therapeutics. Expert Opin. Ther. Pat. 2002, 12, 1491-1501.
6. Whiting, P. J. GABA-A receptors: A viable target for novel anxiolytics?. Curr. Opin. Pharmacol. 2006, 6, 24-29.
7. Mathiasen, L. S.; Rodgers, R. J.; Mirza, N. R. Comparative effects of nonselective and subtype-selective gamma-aminobutyric acidA receptor positive modulators in the rat-conditioned emotional response test. Behav. Pharmacol. 2007, 18, 191-203.
8. Rudolph, U.; Mohler, H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr. Opin. Pharmacol. 2006, 6, 1-6.
9. McKernan, R. M.; Rosahl, T. W.; Reynolds, D. S.; Sur, C.; Wafford, K. A.; Atack, J. R.; Farrar, S.; Myers, J.; Cook, G.; Ferris, P.; Garrett, L.; Bristow, L.; Marshall, G.; Macaulay, A.; Brown, N.; Howell, O.; Moore, K. W.; Carling, R. W.; Street, L. J.; Castro, J. L.; Ragan, C. I.; Dawson, G. R.; Whiting, P. J. Sedative but not anxiolytic properties of benzodiazepine are mediated by the GABAA receptor a1 subtype. Nat. Neurosci. 2000, 3, 587-592.
10. A receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 475-498.
11. Ebert, B.; Wafford, K. A.; Deacon, S. Treating insomnia: current and investigational pharmacological approaches. Pharmacol. Ther. 2006, 112, 612-629.
12. Basile, A. S.; Lippa, A. S.; Skolnick, P. GABAA receptor modulators as anxioselective anxiolytics. Drug Discovery Today: Ther. Strategies 2006, 3, 475-481.
13. Dawson, G. R.; Maubach, K.; Collinson, N.; Cobain, M.; Everitt, B. J.; MacLeod, A. M.; Choudhury, H. I.; McDonald, L. M.; Pillai, G. V.; Rycroft, W.; Smith, A. J.; Sternfeld, F.; Tattersall, D.; Wafford, K. A.; Reynolds, D. S.; Seabrook, G.; Atack, J. R. An inverse agonist selective for alpha5 subunit-containing GABAA receptor enhances cognition. J. Pharmacol. Exp. Ther. 2006, 316, 1335-1345.
14. A receptor as potential target for the treatment of cognitive dysfunction. Drugs Future 2006, 31, 151-162.
15. A circuits in brain development and therapy. Biochem. Pharmacol. 2004, 68, 1685-1690.
16. Mohler, H. Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors. J. Neurochem. 2007, 102, 1-12.
17. A Receptor Subtype-Selective Efficacy: TPA023, an α2/α3 Selective Nonsedating Anxiolytic and α5IA, an α5 Selective Cognition Enhancer. CNS Neurosci. Ther. 2008, 14, 25-35.
18. Pirker, S.; Schwarzer, C.; Wieselthaler, A.; Sieghart, W.; Sperk, G. GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 2000, 101, 815-850.
19. Yee, B. K.; Keist, R.; von Boehmer, L.; Studer, R.; Benke, D.; Hagenbuch, N.; Dong, Y.; Malenka, R. C.; Fritschy, J.-M.; Bluethmann, H.; Feldon, J.; Mohler, H.; Rudolph, U.Aschizophreniarelated sensorimotor deficit links {alpha}3-containing GABAA receptors to a dopamine hyperfunction. Proc. Natl. Acad. Sci. U. S.A. 2005, 102, 17154-17159.
20. A receptors modulate the expression of prepulse inhibition. Mol. Psychiatry 2005, 10, 201-207.
21. Guidotti, A.; Auta, J.; Davis, J. M.; Dong, E.; Grayson, D. R.; Veldic, M.; Zhang, X.; Costa, E. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology 2005, 180, 191-205.
22. Hansch, C.; Leo, A.; Hoeckman, D. Exploring QSAR, Hydrophobic, Electronic, and Steric Constant; ACS Professional References Book; American Chemical Society: Washington, DC, 1995.
23. Costanzo, A.; Guerrini, G.; Ciciani, G.; Bruni, F.; Selleri, S.; Costa, B.; Martini, C.; Lucacchini, A.; Malmberg-Aiello, P.; Ipponi, A. Benzodiazepine Receptor Ligands. 4. Synthesis and Pharmacological evaluation of 3-Heteroaryl-8-chloropyrazolo[5,1-c][1,2,4]-benzotriazine 5-Oxides. J. Med. Chem. 1999, 42, 2218-2226.
24. Costanzo, A.; Guerrini, G.; Ciciani, G.; Bruni, F.; Costagli, C.; Selleri, S.; Besnard, F.; Costa, B.; Martini, C.; Malmberg-Aiello, P. Benzodiazepine receptor ligands. 7. Synthesis and Pharmacological evaluation of new 3-ester of the 8-chloropyrazolo[5,1-c]-[1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl)derivative: an anxioselective agents in rodents. J. Med. Chem. 2002, 45, 5710-5720.
25. Guerrini, G.; Costanzo, A.; Ciciani, G.; Bruni, F.; Selleri, S.; Costagli, C.; Besnard, F.; Costa, B.; Martini, C.; De Siena, G.; Malmberg-Aiello, P. Benzodiazepine receptor ligands. 8: Synthesis and pharmacological evaluation of new pyrazolo[5,1-c]-[1,2,4]benzotriazine 5-oxide 3- and 8-disubstituted: high affinity ligands endowed with inverse-agonist pharmacological efficacy. Bioorg. Med. Chem. 2006, 14, 758-775.
26. Guerrini, G.; Ciciani, G.; Cambi, G.; Bruni, F.; Selleri, S.; Besnard, F.; Montali, M.; Martini, C.; Ghelardini, C.; Galeotti, N.; Costanzo, A. Novel 3-iodo-8-ethoxypyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide as promising lead for design of [alpha]5-inverse agonist useful tools for therapy of mnemonic damage. Bioorg. Med. Chem. 2007, 15, 2573-2586.
27. Guerrini, G.; Ciciani, G.; Cambi, G.; Bruni, F.; Selleri, S.; Melani, F.; Montali, M.; Martini, C.; Ghelardini, C.; Norcini, M.; Costanzo, A. Novel 3-aroylpyrazolo[5,1-c][1,2,4]benzotriazine 5-oxides 8-substituted, ligands at GABAA/benzodiazepine receptor complex: synthesis, pharmacological and molecular modeling studies. Bioorg. Med. Chem. 2008, 16, 4471-4489.
28. Costanzo, A.; Guerrini, G.; Ciciani, G.; Bruni, F.; Costagli, C.; Selleri, S.; Costa, B.; Martini, C.; Malmberg-Aiello, P. Synthesis and Pharmacological evaluation of 3-(2-furyl)- and 3-(3-furyl)-8-chloropyrazolo[5,1- c][1,2,4]benzotriazine 5-oxide new 3-heteroaryl substituted benzodiazepine receptor ligands. Med. Chem. Res. 2002, 11, 87-101.
29. Costanzo, A.; Guerrini, G.; Bruni, F.; Selleri, S. Reactivity of 1-(2-Nitrophenyl)-5-Aminopyrazoles under Basic Conditions and Synthesis of New 3-, 7- and 8-Substituted pyrazolo[5,1-c]-[1,2,4]benzotriazine 5-Oxides as Benzodiazepine Receptor Ligands. J. Heterocycl. Chem 1994, 31, 1369-1376.
30. Starks, M. C.; Liotta, C. Phase Transfer Catalysis, Principles and Techniques; Academic Press: London, 1978.
31. Molander, G. A.; Yun, C.-S. Cross-coupling reactions of primary alkylboronic acids with aryl triflate and aryl halide. Tetrahedron 2002, 58, 1465-1470.
32. Guerrini, G.; Costanzo, A.; Bruni, F.; Ciciani, G.; Selleri, S.; Gratteri, P.; Costa, B.; Martini, C.; Lucacchini, A. Benzodiazepine receptor ligands III. Synthesis and biological evaluation of 2- and/ or 3-substituted pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxides. Il Farmaco 1999, 54, 375-389.
33. Zhang, W.; Koehler, K. F.; Zhang, P.; Cook, J. M. Development of a comprehensive pharmacophore model for benzodiazepine receptor. Drug Des. Discovery 1995, 12, 193-248.
34. Xiaohui, H.; Zhang, C.; Cook, J. M. Model of the BzR binding site: correlation of data from site-directed mutagenesis and the pharmacophore/ receptor model. Med. Chem. Res. 2001, 10, 269-308.
35. Clayton, T.; Chen, J. L.; Ernst, M.; Richter, L.; Cromer, B. A.; Morton, C. J.; Ng, H.; Kaczorowski, C. C.; Helmstetter, F. J.; Furtmuller, R.; Ecker, G.; Parker, M. W.; Sieghart, W.; Cook, J. M. An Updated Unified Pharmacophore Model of the Benzodiazepine Binding Site on -Aminobutyric Acid Receptors: Correlation with Comparative Models. Curr. Med. Chem. 2007, 14, 2755-2775.
36. Guerrini, G.; Costanzo, A.; Bruni, F.; Selleri, S.; Casilli, M. L.; Giusti, L.; Martini, C.; Lucacchini, A.; Malmberg Aiello, P.; Ipponi, A. Benzodiazepine receptor ligands. Synthesis and biological evaluation of 3-, 7-, and 8-substituted pyrazolo[5,1-c]-[1,2,4]benzotriazines and 5-oxide derivatives. Eur. J. Med. Chem 1996, 31, 259-272.
37. Jarvik, M. E.; Kopp, R. An improved one-trial passive avoidance learning situation. Psychol. Rep. 1967, 21, 221-224.